nVerses Capital LLC Buys 1,400 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

nVerses Capital LLC boosted its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 700.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,600 shares of the biotechnology company’s stock after purchasing an additional 1,400 shares during the quarter. nVerses Capital LLC’s holdings in AnaptysBio were worth $54,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its position in shares of AnaptysBio by 1.8% during the second quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock valued at $745,000 after buying an additional 525 shares during the last quarter. Algert Global LLC lifted its position in AnaptysBio by 11.8% during the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after acquiring an additional 1,078 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in AnaptysBio in the first quarter valued at approximately $38,000. Headlands Technologies LLC boosted its stake in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 2,900 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in AnaptysBio by 49.8% in the second quarter. The Manufacturers Life Insurance Company now owns 25,312 shares of the biotechnology company’s stock worth $634,000 after purchasing an additional 8,418 shares during the last quarter.

Insider Activity at AnaptysBio

In other news, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the purchase, the insider now directly owns 7,794,996 shares of the company’s stock, valued at $284,517,354. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were purchased at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the purchase, the insider now owns 7,794,996 shares in the company, valued at $284,517,354. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is owned by corporate insiders.

AnaptysBio Price Performance

ANAB stock opened at $35.37 on Tuesday. The company has a market capitalization of $966.27 million, a P/E ratio of -5.76 and a beta of -0.29. AnaptysBio, Inc. has a 12 month low of $13.36 and a 12 month high of $41.31. The firm’s fifty day simple moving average is $35.46 and its 200-day simple moving average is $29.49.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The business had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. As a group, sell-side analysts forecast that AnaptysBio, Inc. will post -6.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ANAB has been the subject of several analyst reports. Guggenheim increased their price objective on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a report on Monday. Wedbush reiterated an “outperform” rating and issued a $42.00 price target on shares of AnaptysBio in a research note on Thursday, September 26th. JPMorgan Chase & Co. boosted their price target on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Truist Financial increased their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of AnaptysBio in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.64.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.